glp 1 compound ending New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our The GLP-1 drug shortage is

In addition, the narrow age range of the study subjects that was included as a strength to minimize age-related variation limits the extrapolation of the results to other age groups such as children and adults

A combination of genetic and non-genetic factors is responsible for up to 20-fold variation in the warfarin dose required to achieve the usual therapeutic level of anticoagulation as measured by the prothrombin international normalized ratio (INR)

1013 Its antimelanogenic properties result from a variety of mechanisms including stimulation of pheomelanin synthesis rather than darker eumelanin, its antioxidant effects, 14 and interference with intracellular trafficking of melanogenic enzymes

If ongoing trials continue to deliver positive results, triple agonist therapies for diabetes may represent the next major evolution in treating obesity, type 2 diabetes, and related metabolic diseases